Novel targeted treatment options for advanced cholangiocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel targeted treatment options for advanced cholangiocarcinoma

Published:2018-08-30 Issue:9 Volume:27 Page:709-720
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Mahipal Amit¹,Kommalapati Anuhya²,Tella Sri Harsha²^ORCID,Lim Alexander³,Kim Richard⁴

Affiliation:

1. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

2. Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA

3. Department of Internal Medicine, University of South Florida, Tampa, FL, USA

4. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1512581

Reference102 articles.

1. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

2. Risk factors for cholangiocarcinoma

3. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency

4. Biliary papillomatosis with malignant transformation: A case report and review of the literature

5. Genomic spectra of biliary tract cancer

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of maintenance therapy with anlotinib for advanced cholangiocarcinoma after first-line chemotherapy and the variations in efficacy based on different neutrophil-to-lymphocyte ratio (NLR);World Journal of Surgical Oncology;2024-07-29

2. Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors;Discovery Medicine;2024

3. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?;Immunotherapy;2023-05

4. Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue;Frontiers in Oncology;2023-04-24

5. Role of sex in liver tumor occurrence and clinical outcomes: a comprehensive review;Hepatology;2023-01-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3